{"id":56544,"date":"2025-07-18T11:53:36","date_gmt":"2025-07-18T09:53:36","guid":{"rendered":"https:\/\/www.fyb.de\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/"},"modified":"2025-07-18T11:53:36","modified_gmt":"2025-07-18T09:53:36","slug":"arqis-accompanies-evlabio-in-a-e-21-million-seed-round","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/","title":{"rendered":"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round"},"content":{"rendered":"

Munich \u2014 The biotech\u00adno\u00adlogy start-up Evla\u00adBio GmbH, which deve\u00adlops inno\u00adva\u00adtive thera\u00adpies for the treat\u00adment of left ventri\u00adcu\u00adlar hyper\u00adtro\u00adphy in chro\u00adnic kidney dise\u00adase, has raised \u20ac 21 million in its seed finan\u00adcing round. The finan\u00adcing round was led by the French VC firm Kurma Part\u00adners, with AdBio Part\u00adners (Paris, Barce\u00adlona), Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcn\u00adder\u00adfonds as co-inves\u00adtors. The finan\u00adcing round is one of the largest of its kind in the DACH region in recent years. <\/p>\n

Evla\u00adBio aims to acce\u00adle\u00adrate the comple\u00adtion of precli\u00adni\u00adcal deve\u00adlo\u00adp\u00adment and the tran\u00adsi\u00adtion to IND-enab\u00adling studies. \u2014 The start-up\u2019s treat\u00adment approach origi\u00adnally comes from Lead Disco\u00advery Center GmbH (LDC), a company foun\u00added in 2008 by the tech\u00adno\u00adlogy trans\u00adfer orga\u00adniza\u00adtion Max Planck Inno\u00adva\u00adtion<\/strong>, and was deve\u00adlo\u00adped in colla\u00adbo\u00adra\u00adtion with KHAN Tech\u00adno\u00adlogy Trans\u00adfer Fund I GmbH & Co. KG<\/strong> (KHAN\u2011I). <\/p>\n

Evla\u00adBio, with offices in D\u00fcssel\u00addorf and Zurich, is a life science start-up specia\u00adli\u00adzing in the deve\u00adlo\u00adp\u00adment of a first-in-class thera\u00adpeu\u00adtic for the treat\u00adment of left ventri\u00adcu\u00adlar hyper\u00adtro\u00adphy in pati\u00adents with chro\u00adnic kidney disease.<\/p>\n

An ARQIS team led by part\u00adner Dr. Mauritz von Einem, who regu\u00adlarly advi\u00adses start-ups, provi\u00added Evla\u00adBio AG with compre\u00adhen\u00adsive legal support during this finan\u00adcing round. The mandate came about through a perso\u00adnal cont\u00adact with the foun\u00adder of Evla\u00adBio. Adves\u00adtra advi\u00adsed on Swiss law with a team led by Dr. Alex\u00adan\u00adder von Jeinsen. <\/p>\n

Advi\u00adsor Evla\u00adBio GmbH: ARQIS (Munich)<\/strong><\/p>\n

Dr. Mauritz von Einem<\/strong> (Part\u00adner, Tran\u00adsac\u00adtions, Venture Capi\u00adtal, Lead), Johan\u00adnes Landry (Tran\u00adsac\u00adtions, D\u00fcssel\u00addorf), Lisa-Marie Niklas (HR Law, D\u00fcssel\u00addorf), Marcus Noth\u00adhel\u00adfer (IP), of Coun\u00adsel: Prof. Dr. Chris\u00adtoph von Einem (Tran\u00adsac\u00adtions, Venture Capi\u00adtal), Coun\u00adsel: Jens Knip\u00adping (D\u00fcssel\u00addorf), Dennis Reisich (both Tax), Dr. Roua<\/strong> Schmitz (HR Law, Venture Capi\u00adtal), Nora Strat\u00admann (Commer\u00adcial), Mana\u00adging Asso\u00adcia\u00adtes: Dr. Hanna Caesar (HR Law, D\u00fcssel\u00addorf), Anselm Graf (Tran\u00adsac\u00adtions, Venture Capi\u00adtal, Rolf. Roua Schmitz (HR Law), Nora Strat\u00admann (Commer\u00adcial), Mana\u00adging Asso\u00adcia\u00adtes: Dr. Hanna Caesar (HR Law, D\u00fcssel\u00addorf), Anselm Graf (Tran\u00adsac\u00adtions, Venture Capi\u00adtal), Rolf Tichy (IP), Asso\u00adciate: Giulia K\u00f6gel (Tran\u00adsac\u00adtions, Venture Capital).<\/p>\n

About ARQIS
\n<\/strong>
\n ARQIS is an inde\u00adpen\u00addent commer\u00adcial law firm that opera\u00adtes inter\u00adna\u00adtio\u00adnally. Around 80 lawy\u00aders and legal specia\u00adlists advise dome\u00adstic and foreign compa\u00adnies at the highest level on German, Euro\u00adpean and Japa\u00adnese commer\u00adcial law. With its focus groups Tran\u00adsac\u00adtions, HR Law, Japan, Data Law, Risk and Regu\u00adla\u00adtory, the firm is geared towards provi\u00adding its clients with compre\u00adhen\u00adsive advice. The law firm was foun\u00added in 2006 and has offices in D\u00fcssel\u00addorf, Munich and Tokyo as well as a talent hub in Berlin. www.arqis.com.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Munich \u2014 The biotech\u00adno\u00adlogy start-up Evla\u00adBio GmbH, which deve\u00adlops inno\u00adva\u00adtive thera\u00adpies for the treat\u00adment of left ventri\u00adcu\u00adlar hyper\u00adtro\u00adphy in chro\u00adnic kidney dise\u00adase, has raised \u20ac 21 million in its seed finan\u00adcing round. The finan\u00adcing round was led by the French VC firm Kurma Part\u00adners, with AdBio Part\u00adners (Paris, Barce\u00adlona), Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund, NRW.Venture (NRW [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":56542,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-56544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\nARQIS accompanies EvlaBio in a \u20ac 21 million seed round - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"Munich - The biotechnology start-up EvlaBio GmbH, which develops innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, has raised \u20ac 21 million in its seed financing round. The financing round was led by French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcnderfonds as co-investors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Munich - The biotechnology start-up EvlaBio GmbH, which develops innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, has raised \u20ac 21 million in its seed financing round. The financing round was led by French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcnderfonds as co-investors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-18T09:53:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1335\" \/>\n\t<meta property=\"og:image:height\" content=\"977\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round\",\"datePublished\":\"2025-07-18T09:53:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\"},\"wordCount\":416,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\",\"url\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\",\"name\":\"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg\",\"datePublished\":\"2025-07-18T09:53:36+00:00\",\"description\":\"Munich - The biotechnology start-up EvlaBio GmbH, which develops innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, has raised \u20ac 21 million in its seed financing round. The financing round was led by French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcnderfonds as co-investors.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg\",\"width\":1335,\"height\":977,\"caption\":\"Dr. Mauritz von Einem, Partner bei ARQIS in M\u00fcnchen (Foto: Arqis)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round - FYB Financial Yearbook","description":"Munich - The biotechnology start-up EvlaBio GmbH, which develops innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, has raised \u20ac 21 million in its seed financing round. The financing round was led by French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcnderfonds as co-investors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/","og_locale":"en_US","og_type":"article","og_title":"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round - FYB Financial Yearbook","og_description":"Munich - The biotechnology start-up EvlaBio GmbH, which develops innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, has raised \u20ac 21 million in its seed financing round. The financing round was led by French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcnderfonds as co-investors.","og_url":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2025-07-18T09:53:36+00:00","og_image":[{"width":1335,"height":977,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round","datePublished":"2025-07-18T09:53:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/"},"wordCount":416,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/","url":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/","name":"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg","datePublished":"2025-07-18T09:53:36+00:00","description":"Munich - The biotechnology start-up EvlaBio GmbH, which develops innovative therapies for the treatment of left ventricular hypertrophy in chronic kidney disease, has raised \u20ac 21 million in its seed financing round. The financing round was led by French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW Bank) and High-Tech Gr\u00fcnderfonds as co-investors.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/einem-mauritz-von.jpg","width":1335,"height":977,"caption":"Dr. Mauritz von Einem, Partner bei ARQIS in M\u00fcnchen (Foto: Arqis)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/arqis-accompanies-evlabio-in-a-e-21-million-seed-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"ARQIS accompanies EvlaBio in a \u20ac 21 million seed round"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=56544"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/56542"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=56544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=56544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=56544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}